British Journal of Haematology, published by Wiley, is a leading journal in the field of hematology, with an impressive impact factor reflecting its significance in the medical research community. Established in 1955, the journal has consistently contributed to advancing knowledge in hematology, currently holding a prestigious Q1 ranking in the Scopus category of Hematology, placing it in the top 18% of the field. The journal encompasses a broad range of topics including clinical and laboratory aspects of blood disorders and hematological malignancies, making it an essential resource for hematologists, researchers, and healthcare professionals. With its commitment to publishing top-tier research and clinical studies, the British Journal of Haematology plays a critical role in shaping treatment approaches and improving patient outcomes worldwide. Please note that this journal does not offer Open Access options, ensuring that published content is rigorously curated for quality and relevance.

TRANSFUSION CLINIQUE ET BIOLOGIQUE, an esteemed journal published by Elsevier France - Éditions Scientifiques Médicales Elsevier, has been a pivotal resource in the fields of transfusion medicine, biochemistry, and hematology since its inception in 1994. With a strong commitment to advancing scientific knowledge, this journal provides a platform for high-quality research and clinical studies aimed at improving patient care and outcomes in transfusion practices. Although categorized in Q3 and Q4 quartiles across multiple categories in Biochemistry and Medicine for 2023, the journal holds significant potential for growth and impact within the scientific community. While it currently does not offer open access options, its indexing in reputable databases ensures visibility and reach among professionals and researchers. As the field evolves, TRANSFUSION CLINIQUE ET BIOLOGIQUE aims to continue fostering innovation and collaboration, making it a valuable tool for anyone involved in medical, biochemical, and hematological research.

TRANSFUSION AND APHERESIS SCIENCE, published by Pergamon-Elsevier Science Ltd, serves as a pivotal platform for researchers and practitioners in the fields of hematology, transfusion medicine, and apheresis. With an ISSN of 1473-0502 and an E-ISSN of 1878-1683, this peer-reviewed journal boasts a respectable Q3 ranking in the Hematology category as of 2023, positioning it within the 45th percentile among its counterparts. Operating from the United Kingdom, it provides comprehensive insights into the latest advancements and methodologies in transfusion practices and apheresis technology, crucial for enhancing patient care and therapeutic strategies. The journal's scope, covering key developments from 1996 to 2024, allows for a deep exploration of historical and emerging trends within the discipline. Moreover, its open access options facilitate widespread dissemination of research findings, fostering collaboration and innovation in the scientific community. For those dedicated to advancing knowledge in hematology, TRANSFUSION AND APHERESIS SCIENCE represents an essential resource, bridging theory and practice in this vital area of healthcare.

Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.

VOX SANGUINIS is a distinguished peer-reviewed journal in the fields of Hematology and Medicine, published by Wiley, a leading academic publisher based in the United Kingdom. With a rich history dating back to its inception in 1952, this journal has consistently provided a platform for innovative research and insightful reviews, advancing the understanding of blood-related disorders and therapies. As evidenced by its robust performance—ranking #57 out of 137 in Scopus for Medicine in Hematology and holding a Q2 classification in both Hematology and miscellaneous Medicine categories—VOX SANGUINIS is recognized for its significant contributions to the scientific community. This journal serves as a vital resource for researchers, professionals, and students alike, fostering knowledge exchange and collaboration within the field. With its ongoing commitment to quality and integrity, VOX SANGUINIS continues to shape the future of hematological research well into 2024 and beyond.

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

Anemia is a distinguished open-access journal published by HINDAWI LTD, focusing on the intricate and vital field of hematology and related disciplines. Since its inception in 2010, this journal has been dedicated to advancing our understanding of blood disorders, with a particular emphasis on anemia, through the dissemination of high-quality research that is freely accessible to a global audience. The journal's evolving scope from its founding through 2024 embodies its commitment to include the latest breakthroughs and methodologies in cell biology and hematological research. With its presence in prestigious databases and a tiered ranking that places it in the Q3 category in Hematology and Q4 in Cell Biology as of 2023, Anemia serves as an invaluable resource for researchers, clinicians, and students alike. The journal is indexed with a respectable position in Scopus, ranking 52 out of 137 in Hematology, highlighting its growing influence in the medical and scientific communities. With continued emphasis on open access, Anemia not only fosters collaborative research but also ensures that crucial findings reach those who need them most, enhancing educational outcomes and clinical practices worldwide.

Blood Advances is a premier, peer-reviewed journal published by Elsevier, dedicated to the field of hematology. With an impressive impact factor and classified within the Q1 category of hematology for 2023, it ranks as the 16th out of 137 journals in the Scopus Medicine Hematology category, placing it in the top 88th percentile globally. This influential journal, which has been disseminating invaluable research since its inception in 2017, focuses on advancing knowledge and innovation in blood science, including clinical and laboratory aspects of hematology. Although it offers limited open access features, its comprehensive scope encompasses various topics relevant to both researchers and practitioners. Located in the United States and managed from Amsterdam, Blood Advances provides a vital platform for the dissemination of groundbreaking research, making significant contributions to the understanding and treatment of blood disorders. Researchers, professionals, and students alike will find this journal an essential resource for keeping abreast of the latest developments and advancements in hematology.

Clinical Hemorheology and Microcirculation, published by IOS Press, is a distinguished journal dedicated to advancing the scientific understanding of blood flow mechanics and microcirculatory phenomena. Since its inception in 1991, the journal has been pivotal in bridging the fields of cardiology, hematology, and physiology, as evidenced by its placement in the Q3 quartile across several categories in 2023. Positioned in the vibrant academic landscape of the Netherlands, Clinical Hemorheology and Microcirculation offers valuable insights to researchers and practitioners alike, enriching their knowledge and fostering innovation in clinical practices. With an ISSN of 1386-0291 and an E-ISSN of 1875-8622, the journal serves as a vital platform for disseminating high-quality research and reviews that explore the intricate dynamics of blood viscosity and microvascular function, essential to both health and disease. As readers delve into the journal, they will access rigorous studies that not only enhance theoretical understanding but also pave the way for potential clinical applications, making it a crucial resource for those invested in the future of cardiovascular and hematological research.